Tumor Ablation Market

The global tumor ablation market is projected to reach USD 1.89 billion by 2031 from USD 1.10 billion in 2026, at a CAGR of 11.4% during the forecast period. The market for tumor ablation is witnessing sustained growth on account of the growing incidence of cancers, such as liver, lung, kidney, bone, and prostate cancers around the world, where tumor ablation has emerged as a viable alternative to surgery. Growing preferences for minimally invasive therapies compared with conventional surgery have been boosting demand for tumor ablations, owing to factors such as shorter hospital stay times, fewer procedure-related complications, faster recovery times, and the ability to treat patients unfit for surgery due to age and other comorbid conditions. Advances in tumor ablation technology for various energy sources, namely radiofrequency, microwave, cryoablation, laser, HIFU, and IRE, have increased the precision and safety of the procedures, thus encouraging physicians to adopt them more extensively. Other factors fueling the market include a growing number of dedicated cancer centers, increasing expertise of healthcare professionals in image-guided percutaneous procedures, favorable reimbursement policies in several developed countries, and investment in interventional oncology.

Some of the leading companies currently participating in the tumor ablation market are Medtronic (Ireland), Boston Scientific Corporation (US), EDAP TMS (France), Bioventus Inc. (US), and CONMED Corporation (US). These companies are strengthening their market positions through continuous investments in research and development to introduce advanced tumor ablation technologies, including radiofrequency ablation, microwave ablation, cryoablation, laser ablation, high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE) systems. Their focus remains on enhancing treatment precision, procedural efficiency, and clinical outcomes while expanding the applications of minimally invasive tumor ablation across multiple cancer indications.

To know about the assumptions considered for the study download the pdf brochure

To further strengthen their competitive position, these companies are actively pursuing strategic initiatives such as product launches, regulatory approvals, collaborations with hospitals and cancer centers, mergers and acquisitions, and geographic expansion into high-growth emerging markets. Manufacturers are also investing in the development of next-generation ablation generators, probes, electrodes, antennas, cryoprobes, and smart ablation technologies with improved monitoring and control capabilities. In addition, many leading players are expanding physician education and clinical training programs, collaborating with interventional oncology specialists, and participating in clinical research to accelerate technology adoption and improve patient outcomes. These strategies enable companies to enhance their product portfolios, expand their global footprint, and maintain a competitive advantage in the rapidly evolving tumor ablation market. For example, in July 2026, IceCure announced the expanding commercial adoption of ProSense Cryoablation in Brazil.

Medtronic (Ireland)

Medtronic is a healthcare technology company that manufactures, distributes, and sells device-based medical therapies and services. The company operates its business through four operating units: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The Medical Surgical segment includes the Surgical & Endoscopy and Acute Care & Monitoring divisions. The company offers ablation systems under the Surgical & Endoscopy division of medical surgical segment. The Neuroscience segment is further subsegmented into Specialty Therapies, Cranial & Spinal Technologies, and Neuromodulation divisions. The company offers an ablation system for bone tumors and nerve tissue under the Neuromodulation subsegment of the Neuroscience segment. The company has a wider geographic presence in more than 150 countries worldwide. Some of its subsidiaries are Covidien Ltd. (Ireland), Medtronic USA, Inc., and Visualase, Inc. (USA), among others.

Boston Scientific Corporation (US)

Boston Scientific Corporation is a leading manufacturer of medical devices that offers a range of products for interventional medical specialties. The company operates its business through two reportable segments: MedSurg and Cardiovascular. The MedSurg segment is further divided into Endoscopy, Urology, and Neuromodulation subsegments. The Cardiovascular business was earlier divided into Cardiology and Peripheral Interventions; these were combined into a single segment in Q4 2025. The company offers different tumor ablation systems, catheters, and electrodes through the Cardiovascular business segment.

The company has a global presence with 15 manufacturing facilities, including eight in the US and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia, and one in Brazil. The company has various distribution and technology centers globally, with primary customer fulfillment centers in Massachusetts (US), the Netherlands, Malaysia, and Japan.

Market Ranking:

In the global tumor ablation market, Medtronic (Ireland) leads due to its comprehensive radiofrequency, microwave, and cryoablation technologies, global distribution, and strong presence in interventional oncology. It continues to strengthen its leadership through product innovation, acquisitions, and investments in minimally invasive solutions. Boston Scientific (US) is second, supported by advanced cryoablation tech, a robust oncology portfolio, and clinical collaborations. EDAP TMS (France) ranks third with leadership in HIFU technology for prostate cancer, notably its Focal One robotic platform and expanding international adoption. Bioventus (US) has a strong market presence with radiofrequency ablation electrodes and consumables focused on minimally invasive procedures, emphasizing disposable products and expanding globally. CONMED (US) also ranks among the leaders, leveraging expertise in radiofrequency systems and minimally invasive surgical tech. Its investments and partnerships are broadening its market reach and adoption in hospitals and cancer centers.

Related Reports:

Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, HIFU), Product (Systems, Consumables), Application (Liver, Lung, Kidney, Bone Cancer), Procedure (Surgical, Laparoscopic, Percutaneous), and End User - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]